Lipohypertrophy Lipoatrophy Lipodystrophy
Antiretroviral treatment (ART) 1.33 (1.15–1.52)* 1.33 (1.18–1.50)* 1.22 (1.13–1.32)*
ART+gender 1.34 (1.16–1.54)* 1.33 (1.18–1.50)* 1.22 (1.13–1.32)*
ART+age (years) 1.31 (1.14–1.51)* 1.34 (1.18 – 1.52)* 1.22 (1.12–1.32)*
ART+skin color 1.34 (1.16 – 1.54)* 1.34 (1.18–1.51)* 1.23 (1.14–1.33)*
ART, complete model# 1.49 (1.30 – 1.70)* 1.30 (1.15–1.47)* 1.23 (1.13–1.33)*
Protease inhibitors (PI) 1.16 (1.03–1.31)** 1.22 (1.10–1.36)* 1.14 (1.07–1.22)*
PI+gender 1.13 (1.00–1.27)** 1.23 (1.11–1.36)* 1.14 (1.07–1.22)*
PI+age (years) 1.15 (1.02–1.30) 1.22 (1.10–1.36)* 1.14 (1.07–1.21)*
PI+skin color 1.17 (1.04–1.32)** 1.24 (1.12–1.38)* 1.15 (1.08–1.23)*
PI, complete model# 1.23 (1.10–1.38)* 1.20 (1.08–1.32)* 1.15 (1.07–1.22)*
#Adjusted for gender, skin color, smoking status, BMI and CD4
*P value<0.001; **P value 0.01 ≤ P ≤ 0.05;  P value=0.19
Table 6: Modified Poisson regression for risk factors associated with lipohypertrophy, lipoatrophy and lipodystrophy (risk ratio and 95%CI).
Goto home»